Статья
ЭВОЛЮЦИЯ ТРОМБОЛИТИЧЕСКОЙ ТЕРАПИИ В ЛЕЧЕНИИ ИНФАРКТА МИОКАРДА
Отражается краткая история тромболитической терапии (ТЛТ), рассматриваются основные исследования по применению различных тромболитических препаратов в лечении инфаркта миокарда (ИМ) с подъёмом сегмента ST. Освещаются позиции ТЛТ в современном лечении ИМ.
1. Chazov E.I., Ruda M.J. Development of the main directions in the treatment of patients with myocardial infarction in the last 25 years. Cardiology 1989; (11): 11-5. Russian (Чазов Е.И., Руда М.Я. Развитие основных направлений в лечении больных инфарктом миокарда за последние 25 лет. Кардиология 1989;(11): 11-5).
2. Rentrop K.P., Blanke H., Karsch K.R, et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979; 2: 354-63.
3. De Wood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
4. Schroder R., Biamino G., von Leitner E., et al. Intravenose Streptokinase-Infusion beim akutem Myokardinfarkt. Dtsch Med Wschr 1981; 106: 294-7.
5. Gruppo Italiano per lo Studio della Streptochinasi nell’infarcto myocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401.
6. ISIS-2 (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-60.
7. Panchenko E.P., Dobrovolsky A.V. Thrombosis in cardiology. Moscow: SportsandCulture; 1999. Russian (ПанченкоЕ.П., ДобровольскийА.В. Тромбозывкардиологии. М.: Спортикультура; 1999).
8. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
9. Wilcox RG, von der Lippe G, Olsson CG et al. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet 1990;335(8699):1175-8.
10. Third International Study of Infarct Survival Collaborative Group (ISIS 3). A randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet1992; 339: 753-70.
11. Sabadash E. Metalize® – a new era of thrombolytic therapy for acute myocardial infarction. Health of Ukraine, 2004; (98): 4. Ukrainian(Сабадаш Э.Метализе® – новая эра тромболитической терапии острого инфаркта миокарда. Здоровье Украины 2004;(98):4).
12. Tsikouris J.P., Tsikouris A.P. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001 ;21:207-17.
13. Vakili B.A., Kaplan R., Brown D.L. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001; 104: 2171-6.
14. Collen D., Stassen J.M., Yasuda T et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1 -resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994;72:98-104.
15. Cannon C.P, McCabe C.H., Gibson C.M. et al. TN K-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-6.
16. Cannon C.P, Gibson C.M., McCabe C.H. et al. TN K-tissue plasminogen activator compared with frontloaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-14.
17. Van de Werf F., Cannon C.P, Luyten A. et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT- 1 trial. The ASSENT-1 Investigators. Am Heart J 1999;137:786-91.
18. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-22.
19. Van de Werf F, Barron H.V, Armstrong P.W. et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin- specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253-61.
20. Melandri G., Vagnarelli F, Calabrese D. et al. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular Health and Risk Management 2009: 5; 249-56.
21. Sinnaeve P.A., Alexander J.B., Belmans A.C. et al. One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single- bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST- elevation acute myocardial infarction. Am Heart J 2003;146:27-32.
22. Wallentin L., Goldstein P., Armstrong P. et al. Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Acute Myocardial Infarction. Circulation 2003;108: 135-42.
23. Lamfers E., Hooghoudt T., Hertzberger D. et al. Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients’ characteristics, and prognosis. Heart 2003; 89(5): 496-501.
24. Morrison L.J., Verbeek P.R., McDonald A.C. et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283: 2686-92.
25. Van Domburg R.T., Kappetein A.P., Bogers Ad J.J. The clinical outcome after coronary bypass surgery: a 30-year follow-app study. Eur Heart J 2009; 30(4): 453-8.
26. Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010;160(1):30.e1-35.e1.
27. Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368(15):1379-87.
28. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20): 2569-619.